Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 10, 2012 - Issue 7
Submit an article Journal homepage
86
Views
3
CrossRef citations to date
0
Altmetric
Drug Profile

Eplerenone for the treatment of cardiovascular disorders

Masataka Watanabe Department of Epidemiology and Preventive Medicine, Centre of Cardiovascular Research and Education in Therapeutics Monash University, L6, The Alfred Centre, 99 Commercial Road, Melbourne, VIC 3004, Australia
&
Henry Krum Department of Epidemiology and Preventive Medicine, Centre of Cardiovascular Research and Education in Therapeutics Monash University, L6, The Alfred Centre, 99 Commercial Road, Melbourne, VIC 3004, Australia. [email protected]
Pages 831-838 | Published online: 10 Jan 2014

References

  • Tait SA, Tait JF, Coghlan JP. The discovery, isolation and identification of aldosterone: reflections on emerging regulation and function. Mol. Cell. Endocrinol. 217(1–2), 1–21 (2004).
  • Connell JM, Davies E. The new biology of aldosterone. J. Endocrinol. 186(1), 1–20 (2005).
  • Ferrari P, Krozowski Z. Role of the 11β-hydroxysteroid dehydrogenase type 2 in blood pressure regulation. Kidney Int. 57(4), 1374–1381 (2000).
  • Takeda Y. Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralocorticoid receptor antagonist. Hypertens. Res. 27(11), 781–789 (2004).
  • Sun Y, Ramires FJ, Weber KT. Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc. Res. 35(1), 138–147 (1997).
  • Lombès M, Alfaidy N, Eugene E, Lessana A, Farman N, Bonvalet JP. Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 β-hydroxysteroid dehydrogenase in the human heart. Circulation 92(2), 175–182 (1995).
  • Brilla CG, Rupp H, Funck R, Maisch B. The renin-angiotensin-aldosterone system and myocardial collagen matrix remodelling in congestive heart failure. Eur. Heart J. 16(Suppl. O), 107–109 (1995).
  • Roland BL, Krozowski ZS, Funder JW. Glucocorticoid receptor, mineralocorticoid receptors, 11 β-hydroxysteroid dehydrogenase-1 and -2 expression in rat brain and kidney: in situ studies. Mol. Cell. Endocrinol. 111(1), R1–R7 (1995).
  • Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin–angiotensin–aldosterone system. Circulation 83(6), 1849–1865 (1991).
  • Lösel R, Schultz A, Wehling M. A quick glance at rapid aldosterone action. Mol. Cell. Endocrinol. 217(1–2), 137–141 (2004).
  • MacKenzie SM, Fraser R, Connell JM, Davies E. Local renin-angiotensin systems and their interactions with extra-adrenal corticosteroid production. J. Renin. Angiotensin. Aldosterone. Syst. 3(4), 214–221 (2002).
  • Rocha R, Rudolph AE, Frierdich GE et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am. J. Physiol. Heart Circ. Physiol. 283(5), H1802–H1810 (2002).
  • Pitt B, Stier CT Jr, Rajagopalan S. Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease. J. Renin. Angiotensin. Aldosterone. Syst. 4(3), 164–168 (2003).
  • Demers C, McKelvie RS, Yusuf S. The role of digitalis in the treatment of heart failure. Coron. Artery Dis. 10(6), 353–360 (1999).
  • Struthers AD. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J. Card. Fail. 2(1), 47–54 (1996).
  • Smith PJ, Talbert RL. Sexual dysfunction with antihypertensive and antipsychotic agents. Clin. Pharm. 5(5), 373–384 (1986).
  • Aldridge SA. Drug-induced sexual dysfunction. Clin. Pharm. 1(2), 141–147 (1982).
  • Delyani JA. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int. 57(4), 1408–1411 (2000).
  • Cook CS, Berry LM, Bible RH, Hribar JD, Hajdu E, Liu NW. Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans. Drug Metab. Dispos. 31(11), 1448–1455 (2003).
  • Rombouts K, Wielant A, Hellemans K, Schuppan D, Geerts A. Influence of aldosterone on collagen synthesis and proliferation of rat cardiac fibroblasts. Br. J. Pharmacol. 134(1), 224–232 (2001).
  • Sica DA. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail. Rev. 10(1), 23–29 (2005).
  • Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am. J. Hypertens. 15(8), 709–716 (2002).
  • Yamaji M, Tsutamoto T, Kawahara C et al. Effect of eplerenone versus spironolactone on cortisol and hemoglobin A1c levels in patients with chronic heart failure. Am. Heart J. 160(5), 915–921 (2010).
  • Sadée W, Dagcioglu M, Riegelman S. Fluorometric microassay for spironolactone and its metabolites in biological fluids. J. Pharm. Sci. 61(7), 1126–1129 (1972).
  • Tsutamoto T, Wada A, Maeda K et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J. Am. Coll. Cardiol. 37(5), 1228–1233 (2001).
  • Parthasarathy HK, Ménard J, White WB et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J. Hypertens. 29(5), 980–990 (2011).
  • White WB, Duprez D, St Hillaire R et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 41(5), 1021–1026 (2003).
  • Williams GH, Burgess E, Kolloch RE et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am. J. Cardiol. 93(8), 990–996 (2004).
  • Flack JM, Oparil S, Pratt JH et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J. Am. Coll. Cardiol. 41(7), 1148–1155 (2003).
  • Krum H, Nolly H, Workman D et al. Efficacy of eplerenone added to renin–angiotensin blockade in hypertensive patients. Hypertension 40(2), 117–123 (2002).
  • Chapman N, Dobson J, Wilson S et al.; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49(4), 839–845 (2007).
  • Calhoun DA, White WB. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J. Am. Soc. Hypertens. 2(6), 462–468 (2008).
  • Pitt B, Reichek N, Willenbrock R et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 108(15), 1831–1838 (2003).
  • Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341(10), 709–717 (1999).
  • Pitt B, Remme W, Zannad F et al.; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348(14), 1309–1321 (2003).
  • Zannad F, McMurray JJ, Krum H et al.; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364(1), 11–21 (2011)
  • Khan NU, Movahed A. The role of aldosterone and aldosterone-receptor antagonists in heart failure. Rev. Cardiovasc. Med. 5(2), 71–81 (2004).
  • Boccanelli A, Mureddu GF, Cacciatore G et al.; AREA IN-CHF Investigators. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. Eur. J. Heart Fail. 11(1), 68–76 (2009).
  • Udelson JE, Feldman AM, Greenberg B et al. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Circ. Heart Fail. 3(3), 347–353 (2010).
  • Holland DJ, Prasad SB, Marwick TH. Contribution of exercise echocardiography to the diagnosis of heart failure with preserved ejection fraction (HFpEF). Heart 96(13), 1024–1028 (2010).
  • Soylu A, Temizhan A, Duzenli MA, Sokmen G, Koylu O, Telli HH. The influence of aldosterone on the development of left ventricular geometry and hypertrophy in patients with essential hypertension. Jpn. Heart J. 45(5), 807–821 (2004).
  • Deuchar GA, McLean D, Hadoke PW et al. 11ß-hydroxysteroid dehydrogenase type 2 deficiency accelerates atherogenesis and causes proinflammatory changes in the endothelium in apoe-/- mice. Endocrinology 152(1), 236–246 (2011).
  • Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342(3), 145–153 (2000).
  • Dahlöf B, Devereux RB, Kjeldsen SE et al.; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359(9311), 995–1003 (2002).
  • Takeda Y. Role of cardiovascular aldosterone in hypertension. Curr. Med. Chem. Cardiovasc. Hematol. Agents 3(3), 261–266 (2005).
  • Shroff SC, Ryu K, Martovitz NL, Hoit BD, Stambler BS. Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. J. Cardiovasc. Electrophysiol. 17(5), 534–541 (2006).
  • Dixen U, Ravn L, Soeby-Rasmussen C et al. Raised plasma aldosterone and natriuretic peptides in atrial fibrillation. Cardiology 108(1), 35–39 (2007).
  • Nappi JM, Sieg A. Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure. Vasc. Health Risk Manag. 7, 353–363 (2011).
  • Gardiner P, Schrode K, Quinlan D et al. Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. J. Clin. Pharmacol. 29(4), 342–347 (1989).
  • Weinberger MH, White WB, Ruilope LM et al. Effects of eplerenone versus losartan in patients with low-renin hypertension. Am. Heart J. 150(3), 426–433 (2005).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.